Publications

Prise en charge clinique du zona chez les patients atteints de polyarthrite rhumatoïde ou de rhumatisme psoriasique traités par tofacitinib

Rheumatol Ther. 2021. Epub ahead of print. doi: 10.1007/s40744-021-00390-0

Winthrop KL,

Curtis JR,

Yamaoka K,

Lee EB,

Hirose T,

Rivas JL,

Kwok K,

Burmester GR

This post hoc analysis provides the first detailed description of the management and outcomes of HZ events in tofacitinib RA and PsA clinical studies.While prior studies have characterised the increased HZ risk with JAKinibs, the clinical management of these events has not been detailed.To this end, Winthrop, et al. analysed data from 21 RA and 3 PsA clinical studies to evaluate how HZ events and their sequelae were clinically managed during the RA and PsA tofacitinib clinical development progra...

Keywords:

• JAK,
• Tildrakizumab,
• Safety,
• Infections

Points À Considérer Pour le Traitement des Maladies Inflammatoires À Médiation Immunitaire Par les Inhibiteurs de Janus Kinase : Déclaration de Consensus

2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6.

Nash P,

Kerschbaumer A,

Dorner T,

Dougados M,

Fleischmann RM,

Geissler K,

McInnes I,

Pope JE,

van der Heijde D,

Stoffer-Marx M,

Takeuchi T,

Trauner M,

Winthrop KL,

de Wit M,

Aletaha D,

Baraliakos X,

Boehncke W-H,

Emery P,

Isaacs JD,

Kremer J,

Lee EB,

et al

JAKi are approved in various immune-mediated inflammatory diseases. With five JAKi now licensed, this paper reviews key points to consider in their use to assist clinicians, patients, and other stakeholders once the decision is made to commence JAKi.The consensus was developed by a Steering Committee and an expanded Task Force using EULAR standard operating procedures. The committee included patients as well as experts in rheumatology, gastroenterology, haematology, dermatology, and infectious d...

Keywords:

• JAK,
• Review

Innocuité et efficacité du Tofacitinib allant jusqu'à 9,5 ans dans le traitement de la polyarthrite rhumatoïde: résultats finaux d'une étude de prolongation globale, ouverte et à long terme

Arthritis Res Ther. 2019 Apr 5;21(1):89.

Wollenhaupt J,

Lee EB,

Curtis JR,

Silverfield J,

Terry K,

Soma K,

Mojcik C,

DeMasi R,

Strengholt S,

Kwok K,

Lazariciu I,

Wang L,

Cohen S

TOF 5 mg and 10mg BID demonstrated a consistent safety profile and sustained efficacy for up to 9.5 years in this open-label LTE ORAL Sequel study.TOF 5 mg and 10 mg BID demonstrated consistent safety (as monotherapy and combination therapy) and efficacy within this open-label LTE study of RA patients. As RA requires long-term treatment, it’s important to assess the long-term efficacy and safety of RA therapies to understand the potential lifelong impact on patient health and quality of life. Th...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Efficacy,
• LTE

Évaluation des Effets à Court, Moyen et Long Terme du Tofacitinib sur les Lymphocytes Chez les Patients Atteints de Polyarthrite Rhumatoïde

Arthritis Rheumatol 2018 DOI: 10. 1002/art.40780

van Vollenhoven R,

Lee EB,

Strengholt S,

Mojcik C,

Valdez H,

Krishnaswami S,

Biswas P,

Lazariciu I,

Hazra A,

Clark JD,

Hodge J,

Wang L,

Choy E

Tofacitinib (TOF) treatment is associated with short-term transient increases in absolute lymphocyte counts (ALC), followed by a gradual decline to reach steady state by ~48 months. Changes in both ALC and lymphocyte subset counts (LSC) were reversible upon TOF discontinuation. Low ALC but not LSC were associated with an increased risk of serious infective episodes (SIEs) and herpes zoster (HZ). This data supported the treatment recommendations on ALC counts for starting and continuing therapy w...

Keywords:

• JAK,
• Tofacitinib,
• MOA

Tofacitinib dans la polyarthrite rhumatoïde: le manque de changement précoce dans l'activité de la maladie prédit une faible probabilité d’atteindre une activité faible de la maladie au 6ème mois

Arthritis Care Res (Hoboken) 2019 Jan;71(1):71-79. DOI: 10.1002/acr.23585

Van Vollenhoven RF,

Lee EB,

Fallon L,

Zwillich SH,

Wilkinson B,

Chapman D,

Demasi R,

Keystone E

This post-hoc analysis of two, Phase 3 studies, ORAL Start and ORAL Standard shows that early treatment response can predict long-term disease activity outcomes. EULAR recommendations suggest that treat-to-target strategies require regular target assessments with treatment approaches changed if targets are not reached at 6 months. To optimize this strategy, therapy outcomes should be known, and the relationship between short and long-term outcomes defined. The current analysis focused on the dis...

Keywords:

• JAK,
• Tofacitinib,
• Phase 3

Évaluation de l'activité de la maladie chez des patients atteints de polyarthrite rhumatoïde traités au tofacitinib par RAPID3: analyses post-hoc de deux essais de phase 3

Clin Rheumatol 2018 Aug; 37(8):2043–53

Strand V,

Lee EB,

Yazici Y,

Dikranian A,

Wilkinson B,

Takiya L,

Zang C,

Bananis E,

Bergman MJ

Patients given tofacitinib (TOF) who achieved Routine Assessment of Patient Index Data 3 (RAPID3) remission or low disease activity (LDA) at 6 months, had improved long-term outcomes at 2 years, compared to patients with moderate or high disease activity (MDA/HDA) at 6 months.RAPID3¹ is a patient-reported evaluation of disease activity, based on pooled PROs; patient global assessment, patient assessment of arthritic pain and HAQ-DI scores. Previous studies with tocilizumab have suggested that RA...

Keywords:

• JAK,
• Tofacitinib,
• Phase 3

Analysis of Non-melanoma Skin Cancer across the Tofacitinib Rheumatoid Arthritis Clinical Programme

Clin Exp Rheumatol 2017;35:614–22

Curtis JR,

Lee EB,

Martin G,

Mariette X,

Terry TT,

Chen Y,

Geier J,

Andrews J,

Kaur M,

Fan H,

Nduaka CI

Because non-melanoma skin cancer (NMSC) is one of the most common malignancies associated with RA immunomodulatory therapies, this analysis looked to determine the rate of NMSC incidence per 100 patient-years in patients with RA receiving TOF in the clinical trial programme. The Phase 1, 2, and 3 IRs (combined) for both TOF 5- and 10 mg were low and comparable to those of adalimumab, MTX and placebo, IRs remained stable over time. TOF doses used in the 2 Phase 1; 8 Phase 2; and 6 Phase 3 studies...

Keywords:

• JAK,
• Tofacitinib,
• Safety,
• Skin,
• Malignancy

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Ann Rheum Dis 2017;76:1253-1262. DOI 10.1136/annrheumdis-2016-210457

Cohen BS,

Tanaka Y,

Mariette X,

Curtis JR,

Lee EB,

Nash P,

Winthrop KL,

Charles-Shoeman C,

Thirunavukkarasu K,

DeMasi R,

Geier J,

Kwok K,

Wang L,

Riese R,

Wollenhaupt J

This analysis of exposure to tofacitinib, an oral JAKi for the treatment of RA, for up to 8.5 years allowed estimation of safety events with improved precision versus previous tofacitinib reports. Adverse events were generally stable over time; no new safety signals were observed compared with previous tofacitinib reports.Data were collated into an integrated safety summary of tofacitinib in adult patients with active RA, and included data spanning the tofacitinib clinical programme: from 2 Pha...

Keywords:

• JAK,
• Tofacitinib,
• Safety

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-205847. doi: 10.1136/annrheumdis-2014-205847. [Epub ahead of print]

Curtis JR,

Lee EB,

Kaplan IV,

Kwok K,

Geier J,

Benda B,

Soma K,

Wang L,

Riese R

The developments of certain malignancies associated with chronic inflammatory diseases such as RA is known to occur to a greater extent than that of the general population. It is also know that certain RA treatments can affect malignancy rates. As such, newer immunomodulatory agents, such as the JAK inhibitor tofacitinib, are closely monitored for safety events of special interest, including malignancies.

This paper analyses pooled malignancy data from the tofacitinib RA clinical develop...

Keywords:

• JAK,
• Safety,
• Malignancy,
• Review

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Ann Rheum Dis. 2015 Mar 20. pii: annrheumdis-2014-207191. doi: 10.1136/annrheumdis-2014-207191. [Epub ahead of print]

Winthrop KL,

Silverfield J,

Racewicz A,

Neal J,

Lee EB,

Hrycaj P,

Gomez-Reino J,

Soma K,

Mebus C,

Wilkinson B,

Hodge J,

Fan H,

Wang T,

Bingham CO 3rd.

The increased risk of serious infection among RA patients means vaccinations against pneumococcus and influenza are recommended in this group of patients. Studies evaluating immune response to these vaccines in conjunction with DMARD therapy can provide clinicians with important information relating to things such as timing of vaccination.

This study aimed to assess the effect of tofacitinib on vaccine responses to PPSV-23 and the trivalent seasonal influenza vaccine in those whom tofacit...

Keywords:

• JAK,
• Tofacitinib,
• Phase 4,
• Vaccination